155 related articles for article (PubMed ID: 8522468)
41. Pharmacokinetics and safety of single oral doses of lomefloxacin.
Morse IS
Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
[TBL] [Abstract][Full Text] [Related]
42. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers.
Vincent J; Teng R; Dogolo LC; Willavize SA; Friedman HL
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():81-6. PubMed ID: 9222075
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.
Nakashima M; Uematsu T; Kosuge K; Umemura K; Hakusui H; Tanaka M
Antimicrob Agents Chemother; 1995 Jan; 39(1):170-4. PubMed ID: 7695301
[TBL] [Abstract][Full Text] [Related]
44. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers.
Allen A; Bygate E; Faessel H; Isaac L; Lewis A
Int J Antimicrob Agents; 2000 Aug; 15(4):283-9. PubMed ID: 10929878
[TBL] [Abstract][Full Text] [Related]
45. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy.
Andrews JM; Honeybourne D; Brenwald NP; Bannerjee D; Iredale M; Cunningham B; Wise R
J Antimicrob Chemother; 1997 Jun; 39(6):797-802. PubMed ID: 9222050
[TBL] [Abstract][Full Text] [Related]
46. The clinical pharmacokinetics of levofloxacin.
Fish DN; Chow AT
Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
[TBL] [Abstract][Full Text] [Related]
47. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
Nakashima M; Uematsu T; Kosuge K; Kusajima H; Ooie T; Masuda Y; Ishida R; Uchida H
Antimicrob Agents Chemother; 1995 Dec; 39(12):2635-40. PubMed ID: 8592993
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
[TBL] [Abstract][Full Text] [Related]
49. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography.
Teng R; Tensfeldt TG; Liston TE; Foulds G
J Chromatogr B Biomed Appl; 1996 Jan; 675(1):53-9. PubMed ID: 8634768
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of temafloxacin in humans after single oral doses.
Granneman GR; Carpentier P; Morrison PJ; Pernet AG
Antimicrob Agents Chemother; 1991 Mar; 35(3):436-41. PubMed ID: 2039194
[TBL] [Abstract][Full Text] [Related]
51. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.
Bron NJ; Dorr MB; Mant TG; Webb CL; Vassos AB
J Antimicrob Chemother; 1996 Dec; 38(6):1023-9. PubMed ID: 9023649
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of intravenous trovafloxacin in critically ill adults.
Olsen KM; Rebuck JA; Weidenbach T; Fish DN
Pharmacotherapy; 2000 Apr; 20(4):400-4. PubMed ID: 10772370
[TBL] [Abstract][Full Text] [Related]
53. Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.
Hook EW; Pinson GB; Blalock CJ; Johnson RB
Antimicrob Agents Chemother; 1996 Jul; 40(7):1720-1. PubMed ID: 8807070
[TBL] [Abstract][Full Text] [Related]
54. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
Tali-Maamar H; Tebbal S; Rahal K
Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
[TBL] [Abstract][Full Text] [Related]
55. [Trovafloxacin].
Azanza JR; Ollero D; Sádaba B; García Quetglas E
Rev Med Univ Navarra; 1999; 43(1):45-57. PubMed ID: 10386346
[No Abstract] [Full Text] [Related]
56. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
57. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.
Teng R; Dogolo LC; Willavize SA; Friedman HL; Vincent J
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():93-7. PubMed ID: 9222077
[TBL] [Abstract][Full Text] [Related]
58. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
Felmingham D; Robbins MJ; Ingley K; Mathias I; Bhogal H; Leakey A; Ridgway GL; Grüneberg RN
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
[TBL] [Abstract][Full Text] [Related]
59. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
Onderdonk AB
Am J Surg; 1998 Dec; 176(6A Suppl):39S-45S. PubMed ID: 9935256
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.
Ball P; Wilson R; Mandell L; Brown J; Henkel T;
J Chemother; 2001 Jun; 13(3):288-98. PubMed ID: 11450888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
